Avicenna Introduces Machine Learning-Enhanced Medicinal Chemistry Platform to Accelerate the Last Mile of Small Molecule Drug Discovery

DURHAM, N.C.--(BUSINESS WIRE)--Avicenna Biosciences today introduced an extension to its machine learning (ML) technology platform to enhance medicinal chemistry and expedite clinical-stage drug discovery. The company has raised $14.5 million in funding to date, with DCVC Bio leading its 2022 seed round, and this month published a paper in the peer-reviewed Journal of Chemical Information and Modeling. Co-authored with researchers from Schrödinger and Microsoft Research AI4Science, the paper ou